Updates are available Erratum dated 2017-05-09
Click to view Erratum: https://doi.org/10.1038/tp.2017.101
-
Authors
Lemonnier, E
Villeneuve, N
Sonie, S
Serret, S
Rosier, A
Roue, M
Brosset, P
Viellard, M
Bernoux, D
Rondeau, S
Thummler, S
Ravel, D
Ben-Ari, Y
- License Information
-
More Information
Article History
Received: 16 July 2016
Revised: 17 December 2016
Accepted: 9 January 2017
First Online: 14 March 2017
Competing interests
: The study was sponsored by Neurochlore, a biotech company dedicated to the development of novel therapies to autism and other developmental disorders. EL, DR and YB-A are founders and shareholders of the company. The remaining authors declare no conflicts of interest. Funding of the trial comes from an investment of Symmetry Capital, a grant from France's Agence Nationale de la Recherche (ANR-12-RPIB-0001-01) and French Government loans. We are grateful to the Bettencourt-Schuller foundation for support of the experimental investigations on ASD.
